Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis.

Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis.

Lenalidomide could effectively induce red blood cell (RBC) transfusion independence (TI) in patients with lower-risk (Low/Intermediate-1) myelodysplastic syndrome (MDS) with or without 5q deletion. However whether lenalidomide ultimately improves the overall survival (OS) of lower-risk MDS patients...

Full description

Bibliographic Details
Main Authors: Xin-Yue Lian, Zhi-Hui Zhang, Zhao-Qun Deng, Pin-Fang He, Dong-Ming Yao, Zi-Jun Xu, Xiang-Mei Wen, Lei Yang, Jiang Lin, Jun Qian
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5100926?pdf=render

Internet

http://europepmc.org/articles/PMC5100926?pdf=render

Similar Items